HST Global, Inc. Announces Negotiations with Chinese Government

HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC) is pleased to announce that it has, through its contracted partner EBITDA Capital LLC of Newport Beach California and its group of associates, commenced negotiations with the Chinese Government for both direct investment and a license for their treatment protocols.

Mr. Ron Howell, CEO and President of HST Global stated, “Through the use of the EBITDA Capital resources we at HST Global can focus on the issue of bringing awareness of our treatment and solution for late stage cancer treatment to the Chinese community. We want to insure that our treatment is being given every opportunity to be recognized as the medical solution alternative of choice throughout the world.”

One of EBITDA Capital’s tasks was to develop a working relationship with the Chinese Government and Congressman Sarpalius just completed his initial trip to establish the working relationship. After his trip he reported, “Every community in China has a cancer center and the Chinese government is committed to treatment of the disease.” Congressman Sarpalius has commitments from both the government and privately sanctioned investors to commence negotiations with HSTC for both direct investment into HSTC and a license for the treatment protocols. The company expects to host the Chinese delegation within the next thirty days. Ms. Jenny Guo, of Advantage Associates, will host the delegation to be received by Ron Howell in the United States.

About HST Global, Inc.

HST Global, Inc. is a development stage biotechnology company that acquires and develops innovative products for the treatment of cancer. We focus on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer, and then developing those drug candidates for commercial use.

HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.